Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase-deficient mice

Runa S. Naik, Joachim Hartmann, Cornelia Kiewert, Ellen G. Duysen, Oksana Lockridge, Jochen Klein

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Purpose. Alzheimer's disease is characterized by a dysfunction of central cholinergic systems and is treated by inhibitors of acetylcholinesterase (AChE). This study tests the effect of two AChE inhibitors in therapeutic use, rivastigmine and donepezil, in mice that are devoid of AChE (AChE-/- mice). Rivastigmine is an inhibitor of both AChE and butyrylcholinesterase (BChE) whereas donepezil is a selective inhibitor of AChE. Methods. We have used in vivo microdialysis to investigate the effects of the two drugs on the extracellular concentration of acetylcholine (ACh) in the hippocampus of AChE-/- mice. Results. Extracellular ACh levels in the hippocampus were 30-fold elevated in AChE-/- mice compared to wild-type (AChE+/+) animals. Infusion of rivastigmine (1 and 10 μM) caused a further doubling of ACh levels in AChE-/- mice within 90-120 min. In contrast, infusion of donepezil (1 μM) did not affect hippocampal ACh levels in AChE-/- mice although it increased ACh levels more than twofold in wild-type mice. Conclusions. In the absence of AChE, rivastigmine enhances the levels of extracellular ACh by inhibiting BChE. This finding may be of therapeutic relevance because BChE activity is preserved, but AChE activity is strongly decreased, in late-stage Alzheimer's disease.

Original languageEnglish (US)
Pages (from-to)79-85
Number of pages7
JournalJournal of Pharmacy and Pharmaceutical Sciences
Volume12
Issue number1
DOIs
StatePublished - Jan 1 2009

Fingerprint

Rivastigmine
Acetylcholinesterase
Acetylcholine
Brain
Cholinesterase Inhibitors
Butyrylcholinesterase
Hippocampus
Alzheimer Disease
donepezil
Wild Animals
Microdialysis
Therapeutic Uses

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase-deficient mice. / Naik, Runa S.; Hartmann, Joachim; Kiewert, Cornelia; Duysen, Ellen G.; Lockridge, Oksana; Klein, Jochen.

In: Journal of Pharmacy and Pharmaceutical Sciences, Vol. 12, No. 1, 01.01.2009, p. 79-85.

Research output: Contribution to journalArticle

Naik, Runa S. ; Hartmann, Joachim ; Kiewert, Cornelia ; Duysen, Ellen G. ; Lockridge, Oksana ; Klein, Jochen. / Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase-deficient mice. In: Journal of Pharmacy and Pharmaceutical Sciences. 2009 ; Vol. 12, No. 1. pp. 79-85.
@article{b8e0d60cef59411d9ba451e7c5d6fffe,
title = "Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase-deficient mice",
abstract = "Purpose. Alzheimer's disease is characterized by a dysfunction of central cholinergic systems and is treated by inhibitors of acetylcholinesterase (AChE). This study tests the effect of two AChE inhibitors in therapeutic use, rivastigmine and donepezil, in mice that are devoid of AChE (AChE-/- mice). Rivastigmine is an inhibitor of both AChE and butyrylcholinesterase (BChE) whereas donepezil is a selective inhibitor of AChE. Methods. We have used in vivo microdialysis to investigate the effects of the two drugs on the extracellular concentration of acetylcholine (ACh) in the hippocampus of AChE-/- mice. Results. Extracellular ACh levels in the hippocampus were 30-fold elevated in AChE-/- mice compared to wild-type (AChE+/+) animals. Infusion of rivastigmine (1 and 10 μM) caused a further doubling of ACh levels in AChE-/- mice within 90-120 min. In contrast, infusion of donepezil (1 μM) did not affect hippocampal ACh levels in AChE-/- mice although it increased ACh levels more than twofold in wild-type mice. Conclusions. In the absence of AChE, rivastigmine enhances the levels of extracellular ACh by inhibiting BChE. This finding may be of therapeutic relevance because BChE activity is preserved, but AChE activity is strongly decreased, in late-stage Alzheimer's disease.",
author = "Naik, {Runa S.} and Joachim Hartmann and Cornelia Kiewert and Duysen, {Ellen G.} and Oksana Lockridge and Jochen Klein",
year = "2009",
month = "1",
day = "1",
doi = "10.18433/J3MK59",
language = "English (US)",
volume = "12",
pages = "79--85",
journal = "Journal of Pharmacy and Pharmaceutical Sciences",
issn = "1482-1826",
publisher = "Canadian Society for Pharmaceutical Sciences",
number = "1",

}

TY - JOUR

T1 - Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase-deficient mice

AU - Naik, Runa S.

AU - Hartmann, Joachim

AU - Kiewert, Cornelia

AU - Duysen, Ellen G.

AU - Lockridge, Oksana

AU - Klein, Jochen

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Purpose. Alzheimer's disease is characterized by a dysfunction of central cholinergic systems and is treated by inhibitors of acetylcholinesterase (AChE). This study tests the effect of two AChE inhibitors in therapeutic use, rivastigmine and donepezil, in mice that are devoid of AChE (AChE-/- mice). Rivastigmine is an inhibitor of both AChE and butyrylcholinesterase (BChE) whereas donepezil is a selective inhibitor of AChE. Methods. We have used in vivo microdialysis to investigate the effects of the two drugs on the extracellular concentration of acetylcholine (ACh) in the hippocampus of AChE-/- mice. Results. Extracellular ACh levels in the hippocampus were 30-fold elevated in AChE-/- mice compared to wild-type (AChE+/+) animals. Infusion of rivastigmine (1 and 10 μM) caused a further doubling of ACh levels in AChE-/- mice within 90-120 min. In contrast, infusion of donepezil (1 μM) did not affect hippocampal ACh levels in AChE-/- mice although it increased ACh levels more than twofold in wild-type mice. Conclusions. In the absence of AChE, rivastigmine enhances the levels of extracellular ACh by inhibiting BChE. This finding may be of therapeutic relevance because BChE activity is preserved, but AChE activity is strongly decreased, in late-stage Alzheimer's disease.

AB - Purpose. Alzheimer's disease is characterized by a dysfunction of central cholinergic systems and is treated by inhibitors of acetylcholinesterase (AChE). This study tests the effect of two AChE inhibitors in therapeutic use, rivastigmine and donepezil, in mice that are devoid of AChE (AChE-/- mice). Rivastigmine is an inhibitor of both AChE and butyrylcholinesterase (BChE) whereas donepezil is a selective inhibitor of AChE. Methods. We have used in vivo microdialysis to investigate the effects of the two drugs on the extracellular concentration of acetylcholine (ACh) in the hippocampus of AChE-/- mice. Results. Extracellular ACh levels in the hippocampus were 30-fold elevated in AChE-/- mice compared to wild-type (AChE+/+) animals. Infusion of rivastigmine (1 and 10 μM) caused a further doubling of ACh levels in AChE-/- mice within 90-120 min. In contrast, infusion of donepezil (1 μM) did not affect hippocampal ACh levels in AChE-/- mice although it increased ACh levels more than twofold in wild-type mice. Conclusions. In the absence of AChE, rivastigmine enhances the levels of extracellular ACh by inhibiting BChE. This finding may be of therapeutic relevance because BChE activity is preserved, but AChE activity is strongly decreased, in late-stage Alzheimer's disease.

UR - http://www.scopus.com/inward/record.url?scp=70349319533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349319533&partnerID=8YFLogxK

U2 - 10.18433/J3MK59

DO - 10.18433/J3MK59

M3 - Article

C2 - 19470293

AN - SCOPUS:70349319533

VL - 12

SP - 79

EP - 85

JO - Journal of Pharmacy and Pharmaceutical Sciences

JF - Journal of Pharmacy and Pharmaceutical Sciences

SN - 1482-1826

IS - 1

ER -